金河生物科技股份有限公司关于变更保荐机构后重新签订募集资金监管协议的公告

Group 1 - The company has changed its sponsor institution to Ping An Securities for the 2025 private placement of shares, with the original sponsor, Dongfang Securities, transferring its ongoing supervision responsibilities [2] - The company has signed a tripartite supervision agreement with China Minsheng Bank and Ping An Securities to regulate the management and use of raised funds, ensuring the protection of minority investors' rights [2][3] - The total amount raised from the private placement was approximately RMB 820 million, with a net amount of approximately RMB 802 million after deducting issuance costs [2] Group 2 - The tripartite supervision agreement stipulates that the raised funds will be stored in a dedicated account solely for specific projects, including production process efficiency improvements and energy-saving upgrades [3][4] - Ping An Securities will supervise the use of the raised funds and conduct semi-annual inspections of the fund's storage and usage [4][5] - The agreement includes provisions for notification of large withdrawals and compliance with anti-money laundering regulations [5][6] Group 3 - The company has received a new veterinary drug registration certificate for a new inactivated vaccine for swine encephalitis, developed in collaboration with several subsidiaries and partners [14] - The new vaccine is classified as a Class III veterinary drug and is designed to prevent swine encephalitis, with a recommended dosage of 2ml per pig [15][16] - The approval of this new vaccine is expected to enhance the company's product pipeline and strengthen its market position in the animal vaccine sector [20]